PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China.\', \'School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.\', \'CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.\', \'Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201210, China.\', \'CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. Electronic address: suhaixia1@simm.ac.cn.\', \'CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China. Electronic address: ycxu@simm.ac.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0223-5234(22)00032-010.1016/j.ejmech.2022.114130
?:hasPublicationType
?:journal
  • European journal of medicinal chemistry
is ?:pmid of
?:pmid
?:pmid
  • 35114541
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.266
?:rankingScore_hIndex
  • 127
?:title
  • In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all